Datapoint: Libtayo Scores NSCLC Nod, Will Take On Keytruda

Sanofi and Regeneron’s Libtayo last week scored its third FDA approval, this time for first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors have high PD-L1 expression. The drug will now have to face off against Merck’s Keytruda, a behemoth in the competitive lung cancer market basket. For the treatment of NSCLC, Keytruda currently holds preferred formulary placement for 6% of all covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/24/21

0

0

0 Comments

0

0

• Datapoint